Changes in Eevia Health management team - new Commercial manager

Eevia Health Plc ("Eevia" or "The Company") is welcoming Matleena Kotila as the new Commercial manager. At the same time, Tommi Kilpeläinen's contract as Scientific Product Manager was discontinued in the trial period.

Matleena Kotila is a pharmacist and has a career in the sales and marketing of pharmaceuticals, medical devices, and dietary supplements. She comes from a position in Rekitt Benckiser as a Brand activation manager. Matleena will start in Eevia on March 1st, 2023, in a new position as Commercial manager. In this position, she will be responsible for the marketing, sales, customer service, and overall customer front of Eevia.

Simultaneously, Tommi Kilpeläinen's contract as the scientific product manager was discontinued in February 2022 during the trial period, and he now moves on to a position in a large pharmaceutical company in Finland.

The Company's focus on autophagy processes in human cells remains and will be strengthened with different measures during the next few months.

"We are delighted to welcome Matleena as our new Commercial manager. She will bring the needed competence and capacity to bring our products to the nutraceutical industry. With her background in pharmaceuticals, she brings in the knowledge of pharmacology and chemistry, which supports the robust technical inbound marketing model we employ in Eevia.

At the same time, we are sad to see Tommi leaving. Even in the short time he was here, he helped us significantly by focusing more stringently on extracts that support cellular health and autophagy. Eevia wishes Tommi well in the future.

The demand for products with efficacy in autophagy induction (cellular recycling), and cognitive health will skyrocket in the future, and we have other initiatives to ensure progress in this direction," comments Stein Ulve, CEO of Eevia Health Plc.

For further information, please contact:

Stein Ulve, CEO, Eevia Health Plc                          

Email: [email protected]                      

Telephone: +358 400 22 5967  


Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients in dietary supplements and food brands globally. These global brands utilize the ingredients in their consumer product formulas.

Eevia Health is a manufacturer of 100% organically certified plant extracts. Although a significant product, Elderberry extract, is made from cultivated berries, most of Eevia's other raw materials, such as bilberry, lingonberry, chaga-mushroom, and pine bark, are wild-harvested in a sustainable fashion.

Eevia Health operates a modern green-chemistry production facility in Finland. Manufacturing natural ingredients near the raw material harvest areas, Eevia offers a short value chain with an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. Eevia listed its shares at Spotlight Stock Market in Sweden in June 2021, with the short name EEVIA.

To learn more, please visit  or follow Eevia Health on LinkedIn@EeviaHealth.

Om Eevia Health

Eevia Health targets health problems with bioactive extracts from plant material. The human body has an incredible ability to restore good health. However, sometimes the body needs active support. Our mission is to support good health and well-being with plant extracts which have scientifically documented health benefits. Eevia Health manufactures and markets organic ingredients from abundant plant material in the Arctic. Our products are targeted against low-grade inflammation, problems in eye and brain health, and metabolic effects. We collaborate with scientists in Finland and abroad to scientifically substantiate the positive effects of ingredients and also to document the safety of use.



Kurs ()
Förändring ()
Marknad Spotlight stock market Kortnamn EEVIA ISIN-kod FI4000496658


Stein Ulve IR-kontakt [email protected]